Boehringer Ingelheim joined SCRS as a Global Impact Partner

| By | Boehringer Ingelheim, Clinical Trials
851

The Society for Clinical Research Sites (SCRS) announced that Boehringer Ingelheim has joined the organization as a Global Impact Partner (GIP). SCRS’ GIP Program provides a unique opportunity for sponsors, CROs and vendors to engage with SCRS and its members in an impactful manner.

Becoming a GIP demonstrates the company’s commitment to clinical research sites and their desire to develop a deeper understanding of the needs of sites, and contribute to the development and implementation of solutions.

“We look forward to working with SCRS to identify innovative approaches to working with sites as partners and to collaborate with other industry leaders to advance the clinical trial process”, said Theresa Devins, senior associate director for Boehringer Ingelheim. “With SCRS’ global reach, there is great potential in developing synergies across our organizations internationally and domestically. We are excited to join SCRS as a Global Impact Partner”

Founded in 2012, SCRS is a global trade organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,000 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, connectivity and mentorship.

SOURCE: scrs
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.